DHAVAL SHAH, MD

Leuprolide acetate (for depot suspension), 7.5 mg

Injection, fosnetupitant 235 mg and palonosetron 0.25 mg

Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l

Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg

Administration of chemotherapy into vein, 1 hour or less

Injection, zoledronic acid, 1 mg

New patient office or other outpatient visit, 60-74 minutes

Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes

Administration of additional new drug or substance into vein, 1 hour or less

Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

Established patient office or other outpatient visit, 40-54 minutes

Injection, carboplatin, 50 mg

Administration of additional new drug or substance into vein using push technique

Infusion into a vein for hydration, 31-60 minutes

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes

Established patient office or other outpatient visit, 30-39 minutes

Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes

Administration of chemotherapy into vein, each additional hour

Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less

Established patient office or other outpatient visit, 20-29 minutes

Injection, pembrolizumab, 1 mg

Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle

Injection, daratumumab, 10 mg and hyaluronidase-fihj

Injection, palonosetron hcl, 25 mcg

Irrigation of implanted venous access drug delivery device

Injection of additional new drug or substance into vein

Telephone medical discussion with physician, 5-10 minutes

Infusion into a vein for therapy, prevention, or diagnosis, each additional hour

Injection of drug or substance under skin or into muscle

Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion

Established patient office or other outpatient visit, 10-19 minutes

Injection, nivolumab, 1 mg

Injection, ferric derisomaltose, 10 mg

Injection, docetaxel, 1 mg

Injection, denosumab, 1 mg

Collection of blood sample from implanted device

Injection, oxaliplatin, 0.5 mg

Injection, leucovorin calcium, per 50 mg

Injection, granisetron hydrochloride, 100 mcg

Injection, darbepoetin alfa, 1 microgram (non-esrd use)

Infusion, normal saline solution , 1000 cc

Injection, fluorouracil, 500 mg

Injection, diphenhydramine hcl, up to 50 mg

Injection, magnesium sulfate, per 500 mg

Injection, ondansetron hydrochloride, per 1 mg

Injection, paclitaxel, 1 mg

Injection, dexamethasone sodium phosphate, 1 mg